Idera Pharma (IDRA) Reports In-Line Q3 Loss; Discontinues IMO-2125 Testing
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts IDRA Hot Sheet
Join SI Premium – FREE
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) reported Q3 loss of ($0.20), in-line with the analyst estimate of ($0.20). Revenue for the quarter came in at $4 million versus the consensus estimate of $2 million.
Based on its strategic assessment and prioritization, the Company has discontinued further development of IMO-2125 in hepatitis C virus infection and decided to advance its TLR-targeted programs in infectious diseases, respiratory diseases, hematologic oncology, and additional vaccine adjuvant applications only through licensing and partnering.
Based on its strategic assessment and prioritization, the Company has discontinued further development of IMO-2125 in hepatitis C virus infection and decided to advance its TLR-targeted programs in infectious diseases, respiratory diseases, hematologic oncology, and additional vaccine adjuvant applications only through licensing and partnering.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ardent Health Partners, Inc. (ARDT) Tops Q3 EPS by 8c; offers guidance
- Viemed Healthcare, Inc. (VMD) Misses Q3 EPS by 2c; updates guidance
- NewAmsterdam Pharma Company N.V. (NAMS) Tops Q3 EPS by 35c
Create E-mail Alert Related Categories
Earnings, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
